“A fresh wave of gene-editing therapies is surging to the fore — even as the field wrestles with the challenge of getting the first generation of expensive and complex CRISPR treatments to the people who need them.

Barely a year after the first government approval for a gene-editing therapy, researchers at the American Society of Hematology’s annual meeting in San Diego, California, presented data on gene-editing approaches for treating cancer and blood disorders, and for making stem-cell transplants safer. They also unveiled good news about the first approved treatment: benefits from the therapy, called Casgevy, can last for at least five years in people with either of two heritable blood disorders, sickle-cell disease and β-thalassaemia. Casgevy gained its first government approval little more than a year ago.”

From Nature.